Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Brian Powl sold 4,345 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.89, for a total transaction of $51,662.05. Following the transaction, the insider directly owned 169,269 shares of the company's stock, valued at $2,012,608.41. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Kura Oncology Trading Up 4.3%
Shares of KURA stock opened at $12.40 on Tuesday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market cap of $1.10 billion, a P/E ratio of -3.68 and a beta of 0.38. The company has a 50 day moving average of $10.59 and a 200-day moving average of $9.50. Kura Oncology, Inc. has a 12-month low of $7.36 and a 12-month high of $12.90.
Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million for the quarter, compared to the consensus estimate of $20.16 million. Sell-side analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts recently weighed in on the company. Wall Street Zen raised Kura Oncology from a "strong sell" rating to a "hold" rating in a report on Saturday, May 16th. Raymond James Financial set a $24.00 target price on shares of Kura Oncology in a research note on Monday. Sanford C. Bernstein set a $24.00 price target on shares of Kura Oncology in a research note on Monday, June 15th. Citigroup reaffirmed a "market outperform" rating on shares of Kura Oncology in a report on Monday. Finally, Wells Fargo & Company set a $24.00 price objective on shares of Kura Oncology in a research note on Thursday, June 4th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $25.40.
View Our Latest Report on KURA
Institutional Investors Weigh In On Kura Oncology
A number of institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System grew its stake in Kura Oncology by 968.0% during the second quarter. California State Teachers Retirement System now owns 1,017,939 shares of the company's stock valued at $11,167,000 after acquiring an additional 922,622 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Kura Oncology in the 2nd quarter worth approximately $243,000. Hsbc Holdings PLC lifted its stake in Kura Oncology by 6.5% in the 2nd quarter. Hsbc Holdings PLC now owns 94,810 shares of the company's stock worth $1,055,000 after purchasing an additional 5,778 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in Kura Oncology in the 2nd quarter valued at $621,000. Finally, Corient Private Wealth LP bought a new position in Kura Oncology in the 2nd quarter valued at $1,344,000.
Kura Oncology Company Profile
(
Get Free Report)
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura's research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company's lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
